Industry: Pharmaceuticals, Biotechnology
Biosynexus Incorporated is a privately held biotechnology-pharmaceutical company that is commercializing a portfolio of protein-based products – monoclonal antibodies, enzymes and peptides – for the prevention and treatment of hospital acquired infections. The company is focusing its initial efforts on developing products for the prevention of staphylococcal (“staph”) infections, the leading cause of infection in hospitals and other medical care facilities. Biosynexus has a strategic partnership with GSK Biologicals, a division of GlaxoSmithkline, for the co-development and marketing of the Company’s lead product, BSYX-A110, currently in Phase II clinical trials. BSYX-L210, lysostaphin cream for the eradication of S. aureus nasal carriage will be entering phase II studies in 2004. ( www.biosynexus.com )
Biosynexus Incorporated
9298 Gaither Road
Gaithersburg, Maryland 20877
USA
Tel: (301) 330-5800